Otsuka Holdings (OTSKY) Fair Value & Analysis
Healthcare · US · Market cap $35.4B
Otsuka Holdings
OTSKY · US
Fair value as of: Jul 17, 2026
From 26 valuation models · updated today
Share price +1.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $21.57 – $36.89 · fair‑value band $28.52 – $56.78 · the $33.91 price screens below the $44.89 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Otsuka Holdings (OTSKY) currently trades at $33.91, while our model-based Fair Value estimate is $44.89, implying the stock looks roughly 32.4% undervalued today. We read business quality at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Otsuka Holdings generated revenue of $2.5T at a net margin of 15.0%. Revenue grew 8.2% year over year. It earns a return on equity of 12.9%. The balance sheet holds a net cash position of $307B. Fundamentals as of Jul 17, 2026
Our scenario range runs from $28.52 (bear case) to $56.78 (bull case); at $33.91, the current price sits within that range. The share trades about 10% below its 52-week high and 57% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -36% fair-value upside, at 32%, OTSKY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Otsuka Holdings reported revenue of $2.6T in FY2025 versus $1.5T in FY2021, a compound +14.6%/yr. Reported net income was $381B in FY2025, compounding +32.0%/yr from FY2021.
Is OTSKY fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,131 | $447.74 | -60% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc 4AB | €201.00 | €93.51 | -53% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| Novartis AG NVSN | 2,601 MXN | 1,897 MXN | -27% |
| AstraZeneca PLC ZEG | €160.70 | €86.60 | -46% |
| Novo Nordisk A/S NOVOB | kr 307.75 | kr 542.67 | +76% |
| Amgen Inc AMGN | $345.60 | $219.60 | -36% |
| Gilead Sciences, Inc GILD34 | R$337.84 | R$214.60 | -36% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Otsuka Holdings (OTSKY) undervalued?
What is the fair value of OTSKY?
What is the quality score of OTSKY?
What is the revenue of Otsuka Holdings (OTSKY)?
What is the net profit margin of OTSKY?
Does Otsuka Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Otsuka Holdings reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Otsuka Holdings materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.